Since the discovery of the relationship between inflammation and cancer in 1863 by R Virchow (11), inflammatory indicators such as neutrophil-lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), lymphocyte to monocyte ratio (LMR), regulatory T cells and peripheral memory CD4+ T cell, have been used in predicting efficacy and survival in different kinds of cancer (12–16). Here, CD4 is linked to cancer.